2H8I image
Deposition Date 2006-06-07
Release Date 2007-06-19
Last Version Date 2024-10-16
Entry Detail
PDB ID:
2H8I
Keywords:
Title:
Crystal Structure of the Bothropstoxin-I complexed with polyethylene glycol
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.27
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 31 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Phospholipase A2 homolog 1
Chain IDs:A, B
Chain Length:121
Number of Molecules:2
Biological Source:Bothrops jararacussu
Ligand Molecules
Primary Citation
Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues
Toxicon 49 378 387 (2007)
PMID: 17157889 DOI: 10.1016/j.toxicon.2006.10.011

Abstact

Lys49 phospholipase A2 homologues are highly myotoxic and cause extensive tissue damage but do not display hydrolytic activity towards natural phospholipids. The binding of heparin, heparin derivatives and polyanionic compounds such as suramin result in partial inhibition (up to 60%) of the myotoxic effects due to a change in the overall charge of the interfacial surface. In vivo experiments demonstrate that polyethylene glycol inhibits more than 90% of the myotoxic effects without exhibiting secondary toxic effects. The crystal structure of bothropstoxin-I complexed with polyethylene glycol reveals that this inhibition is due to steric hindrance of the access to the PLA2-active site-like region. These two inhibitory pathways indicate the roles of the overall surface charge and free accessibility to the PLA2-active site-like region in the functioning of Lys49 phospholipases A2 homologues. Molecular dynamics simulations, small angle X-ray scattering and structural analysis indicate that the oligomeric states both in solution and in the crystalline states of Lys49 phospholipases A2 are principally mediated by hydrophobic contacts formed between the interfacial surfaces. These results provide the framework for the potential application of both clinically approved drugs for the treatment of Viperidae snakebites.

Legend

Protein

Chemical

Disease

Primary Citation of related structures